Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

Crippa, Flavio; Buraggi, G.L.; Re, E. Di; Gasparini, M; Seregni, Ettore; Canevari, Silvana; Gadina, Massimo; Presti, M.; Marini, A.; Seccamani, E.

doi:10.1016/0277-5379(91)90174-c

Cited by 61 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…of patients 13-45) for different kinds of adenocarcinomatous lesions [4,9,16,20,24,25]. The high value of 96.6% for locoregional specificity confirms the results of a pilot clinical trial using 99mTc-MAb-170 that showed no false-positive result in six patients with cancer of the ovary or the fallopian tube [15].…”

Section: Discussionsupporting

confidence: 73%

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

et al. 1995

View full text Add to dashboard Cite

The recently developed technetium-99m-labelled monoclonal antibody-170 (MAb-170) was designed for diagnostic use in patients suffering from gynaecological adenocarcinoma. Following in vitro studies which showed immunoreactivity of this antibody to more than 90% of human adenocarcinomas, the present investigation was initiated to verify its usefulness for radioimmunoscintigraphy of ovarian tumours. Most of the 30 patients participating in this study underwent immunoscintigraphy prior to first-look surgery. Biokinetic evaluation in two patients showed a plasma half-time of 18.9 h (mean value, n = 2, r = 0.98) and a biexponential total body curve with values of 7.7 h and 17 days (r = 0.98). The mean 24-h urinary excretion was 12% of the injected dose. Radioimmunoscintigraphy using the MAb-170 recognised 12 of 13 cases of adenocarcinoma of the ovaries, corresponding to an overall sensitivity of 92.3%. Specificity was 94.1% (16/17). The calculation of accuracy yielded a figure of 93.3% (28/30). Of 33 known lesions, 26 were visualised successfully; thus the locoregional sensitivity was 78.8%. Of 29 benign tumour sites, 28 showed no evidence of tracer accumulation, corresponding to a locoregional specificity of 96.6%. The smallest lesion visualised was an adenocarcinoma of the corpus uteri with a diameter of 1.5 cm. Technetium-99m labelled MAb-170 is a promising new radiopharmaceutical for immunoscintigraphy of ovarian adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 73%

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

et al. 1995

View full text Add to dashboard Cite

show abstract

“…injection of radiolabelled H M F G 2 in ovarian cancer patients. In the work of Crippa et al (1991), the authors compared intravenous with intraperitoneal injection of MOv18 in 30 patients with ovarian cancer, showing a higher tumour uptake and a better tumour to background ratio after i.p. injection.…”

Section: Discussionmentioning

confidence: 99%

“…administration is superior to i.v. administration, leading to a better tumour to background ratio and higher %i.d./g of tumour for intraperitoneal tumour implants Colcher et al 1987;Crippa et al 1991).…”

Section: Introductionmentioning

confidence: 99%

Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

Paganelli¹,

Belloni²,

Magnani³

et al. 1992

Eur J Nucl Med

View full text Add to dashboard Cite

A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 micrograms of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14% i.d. (range 8-18% i.d.) was found in the urine, 14% i.d. (range 6-29% i.d.) in the blood and 63% i.d. (range 56-70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.

show abstract

“…The antibody OV 197 is unique and binds to a third domain designated C. (7,8) MOv18 is a monoclonal antibody reacting with a surface antigen which is expressed on about 90% of all human ovarian carcinomas (9). It has been used for immunoscintigraphy (10) and radioimmunotherapy (6) in patients with ovarian cancer, with promising results.…”

mentioning

confidence: 99%

Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with¹²⁵I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts

Andersson

Lindegren²,

Bäck³

et al. 1999

Acta Oncologica

View full text Add to dashboard Cite

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

Cited by 61 publications

References 14 publications

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with¹²⁵I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts

Contact Info

Product

Resources

About

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

Cited by 61 publications

References 14 publications

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with125I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts

Contact Info

Product

Resources

About

Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with¹²⁵I According to the m-MeATE Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts